Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
The Pharma Letter17h
BridgeBio’s Beyonttra approved in Japan
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
BridgeBio announces Japanese MHLW approved acoramidis for treating ATTR-CM
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
Zacks Investment Research on MSN2d
4 Tech Stocks Penetrating the Health and Fitness Wearables Market
The healthcare and fitness wearables landscape is transforming rapidly, with tech giants investing heavily to improve the ...
Alexion’s ravulizumab granted FDA orphan designation
Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
PharmExec9d
Phase III Trial Data Show Eneboparatide Normalizes Serum Calcium Levels in Chronic Hypoparathyroidism
In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...
The American Journal of Managed Care12d
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...